GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » ROC %

Synergy Pharmaceuticals (FRA:S90) ROC % : -184.52% (As of Sep. 2018)


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Synergy Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Sep. 2018 was -184.52%.

As of today (2024-05-17), Synergy Pharmaceuticals's WACC % is 0.00%. Synergy Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Synergy Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Synergy Pharmaceuticals ROC % Historical Data

The historical data trend for Synergy Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals ROC % Chart

Synergy Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,976.90 -13,297.22 -12,596.15 -16,289.89 -17,796.97

Synergy Pharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6,499.39 -6,483.17 -3,874.43 -1,802.79 -184.52

Synergy Pharmaceuticals ROC % Calculation

Synergy Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2017 is calculated as:

ROC % (A: Dec. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2016 ) + Invested Capital (A: Dec. 2017 ))/ count )
=-187.758 * ( 1 - 0% )/( (0.88800000000001 + 1.222)/ 2 )
=-187.758/1.055
=-17,796.97 %

where

Invested Capital(A: Dec. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=85.18 - 27.9 - ( 78.103 - max(0, 27.9 - 84.292+78.103))
=0.88800000000001

Synergy Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2018 is calculated as:

ROC % (Q: Sep. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2018 ) + Invested Capital (Q: Sep. 2018 ))/ count )
=-101.496 * ( 1 - -3.39% )/( (5.799 + 107.942)/ 2 )
=-104.9367144/56.8705
=-184.52 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2018) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synergy Pharmaceuticals  (FRA:S90) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Synergy Pharmaceuticals's WACC % is 0.00%. Synergy Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Synergy Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Synergy Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Synergy Pharmaceuticals (FRA:S90) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines